
Sean Whooley
Assistant Editor, Life Sciences at MassDevice
Assistant Editor, Life Sciences at Drug Discovery & Development
Assistant Editor, Life Sciences at Medical Tubing + Extrusion
Assistant Editor, Life Sciences at WTWH Media LLC
Assistant Editor at @MassDevice/@WTWH_Media
Articles
-
6 days ago |
massdevice.com | Sean Whooley
The FDA today issued an alert related to a potentially high-risk device issue with certain Conavi Novasight Hybrid catheters. Its communication comes as part of its pilot to enhance the medical device recall program. The FDA said it became aware of the issue after Conavi sent a letter to affected customers recommending the removal of certain catheters. The communication relates to the Novasight Hybrid catheter (TA-06-0001). Affected lot numbers include 230902, 240202, 240302, 240402 and 240502.
-
6 days ago |
drugdeliverybusiness.com | Sean Whooley
Tidepool announced today that it secured a new certification for its open-source quality management system, known as qmsOS. Palo Alto, California-based Tidepool, a non-profit diabetes data management group, develops open-source technology for the diabetes community. That includes the FDA-cleared Tidepool Loop, a “do-it-yourself” (DIY) automated insulin delivery (AID) system. Recent collaborations include integrations with Abbott and Sequel Med Tech, among others.
-
6 days ago |
massdevice.com | Sean Whooley
Sanoculis announced that it received CE mark for its MINT (minimally invasive nasal trabeculostomy) product. MINT, a stent-free platform, helps treat adult patients undergoing glaucoma angle surgery. The system utilizes a unique mechanical, semi-automated trephination technology. Its cutting-edge diameter of 0.14 mm creates precise openings in the pigmented trabecular meshwork.
-
6 days ago |
massdevice.com | Sean Whooley
BVI Medical announced that it received FDA 510(k) clearance for its Leos (laser endoscopy ophthalmic system) for treating glaucoma. Waltham, Massachusetts-based BVI designed Leos for a more intuitive laser endoscopic cyclophotocoagulation (ECP) procedure. It aims to integrate seamlessly into the surgical workflow while treating glaucoma.
-
6 days ago |
massdevice.com | Sean Whooley
Edwards Lifesciences (NYSE: EW) today announced eight-year data highlighting positive long-term outcomes with its proprietary Resilia tissue. Irvine, California-based Edwards — a leader in heart valve technology — designed its Resilia technology to extend valve durability. It utilizes bovine pericardial tissue treated with anti-calcification technology, to serve as the platform for Edwards’ new class of valves.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →Coverage map
X (formerly Twitter)
- Followers
- 145
- Tweets
- 19
- DMs Open
- No

RT @FPW_MaryGannon: Here's a look at the e-chain @igus_HQ is able to manufacture from the recycled energy chains it receives through its th…

RT @wtwh_paulheney: Benefits of drylin technology: no greasing, reduces weight up to 75%, operates in dirty environments, vibration dampeni…

RT @wtwh_paulheney: Nicole Lang discusses igus plastic bearings. They now have 55 materials in their catalog, along with 100s more in devel…